Valuation : NEOVACS

Market Cap 4.09T 4.75T 3.87T 3.51T 6.58T 5L 6.62T 45.98T 17.68T 2L 17.82T 17.43T 7L P/E 2023 *
-
P/E 2024 -
Enterprise Value -2L -2L -2L -2L -3L -2.23Cr -3L -22.6L -9L -1.13Cr -9L -9L -3.58Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day-6.25%
1 week-18.92%
Current month-25.00%
1 month-62.50%
3 months-85.00%
6 months-97.27%
Current year-99.66%
1 week 0.28
Extreme 0.28
0.46
1 month 0.28
Extreme 0.28
0.89
Current year 0.28
Extreme 0.28
267
1 year 0.28
Extreme 0.28
4,200
3 years 0.28
Extreme 0.28
3,20,00,000
5 years 0.28
Extreme 0.28
35,19,20,000
10 years 0.28
Extreme 0.28
35,19,20,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Date Insider Type Main position Quantity % Market Cap. Importance
27/02/21 Sell

Chief Executive Officer

25,05,144 1.3796%
23/02/21 Sell

Chief Executive Officer

63,91,053 3.5196%
23/02/21 Sell

Chief Executive Officer

11,08,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-6.25%-18.92%-99.99%-100.00% 55.38T
-0.71%-6.35%-2.99%+9.59% 4.55TCr
+0.21%-2.98%+337.74%+519.55% 4.37TCr
+1.74%-2.24%+39.82%+20.76% 4.31TCr
+1.38%-3.28%+6.84%+67.62% 3.94TCr
-1.44%-5.26%+8.97%+39.76% 3.19TCr
+0.87%-2.60% - - 1.73TCr
+0.75%-0.64%+19.75%+110.17% 1.64TCr
-0.31%-2.78%+10.78%+31.02% 1.42TCr
+1.93%-3.55%+82.00%+41.17% 1.33TCr
Average -0.18%-5.11%+44.77%+82.18% 2.65TCr
Weighted average by Cap. +0.41%-3.67%+74.57%+124.26%

Financials

2023 2024
Net sales 5L 6L 5L 5L 9L 5.91Cr 9L 59.99L 23.07L 3.01Cr 23.25L 22.74L 9.51Cr 4L 5L 4L 4L 7L 4.81Cr 7L 48.8L 18.77L 2.45Cr 18.91L 18.5L 7.74Cr
Net income -87.43L -1.01Cr -82.79L -75.04L -1.41Cr -97Cr -1.41Cr -9.83Cr -3.78Cr -49Cr -3.81Cr -3.73Cr -155.86Cr -3.29Cr -3.82Cr -3.12Cr -2.82Cr -5.3Cr -364.96Cr -5.33Cr -37Cr -14Cr -185.68Cr -14Cr -14Cr -586.71Cr
Net Debt -2L -3L -2L -2L -4L -2.62Cr -4L -26.6L -10.23L -1.33Cr -10.31L -10.08L -4.22Cr -2L -2L -2L -2L -3L -2.27Cr -3L -23.06L -9L -1.16Cr -9L -9L -3.66Cr
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
11/26/11 €0.3000 -6.25% 55,556
10/26/10 €0.3200 -8.60% 40,202
09/26/09 €0.3501 +2.97% 1,33,064
08/26/08 €0.3400 -8.11% 14,336
07/26/07 €0.3700 0.00% 9,129
  1. Stock Market
  2. Stocks
  3. ALNEV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!